Biologics Fill / Finish Services Market, 2019-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Biologics Fill / Finish Services Market, 2019 – 2030” report has been added to ResearchAndMarkets.com’s offering.

The Biologics Fill / Finish Service Providers, 2019-2030 report features an extensive study on the contract service providers offering drug product manufacturing services within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of companies that claim to specialize in fill/finish operations.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as growth of the overall biopharmaceutical market, cost of goods sold, direct manufacturing costs, share of drug product manufacturing costs, and outsourcing trends related to fill / finish operations, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the period 2019-2030.

Year-wise projections of the current and future opportunity have further been segmented on the basis of:

• A. Types of primary packaging containers used for fill / finish (ampoules, cartridges, syringes and vials)
• B. Types of biologics (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, viral products, oligonucleotides and others)
• C. Company size (small-sized, mid-sized and large / very large)
• D. Scale of operation (preclinical, clinical and commercial)
• E. Key therapeutic areas (cancer, infectious diseases, autoimmune diseases, cardiovascular diseases and other indications)
• F. Key geographical regions (North America (US, Canada), Europe (UK, France, Germany, Italy, Spain and Rest of the Europe), Asia-Pacific (Japan, China, South Korea, India and Australia)). To account for the uncertainties associated with the fill/finish of biopharmaceuticals and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

Amongst other elements, the report includes:

• A detailed review of the overall landscape of contract fill / finish services market for biopharmaceuticals, featuring a list of active service providers and detailed analysis based on a number of relevant parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics filled (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, viral products, oligonucleotides and others), year of establishment, company size and geographical location of the service provider, count and location of affiliated fill / finish facilities, number of additional services offered (lyophilization, labelling, quality testing, storage and distribution services), dosage forms handled (liquid and lyophilized), and types of primary packaging containers handled (ampoules, cartridges, syringes and vials), including details on fill / finish capacity and fill volume range.
• A region-wise, company competitiveness analysis, highlighting prominent fill/finish service providers across various packaging types, based on supplier strength (considering experience and company size of the service provider), service strength (considering number of fill / finish facilities, number of continents where the aforementioned facilities are located, number of additional services offered and scale of operation) and types of biologics handled.
• Elaborate profiles of key players across key geographies (North America, Europe and Asia-Pacific), which were shortlisted based on our proprietary company competitiveness analysis. Each profile provides an overview of the company, information on its overall service portfolio, fill/finish facilities, financial performance (if available), and details on partnerships, expansions and recent awards and accolades, as well as an informed future outlook.
• An analysis of the recent collaborations (signed since 2013) focused on the contract fill / finish services for biologics, based on various parameters, such as year of agreement, type of agreement, scale of operation of the project, focus area, types of services mentioned in the deal, types of biologics involved and location of facility where the project is to be executed.
• A detailed analysis of the expansions undertaken (since 2013) by various service providers for augmenting their respective fill / finish service portfolios, based on a number of parameters, including year of expansion, type of expansion (capacity expansion and new facility), geographical location of facility, type of packaging container involved, scale of operation (as mentioned in the expansion terms), types of services and biologics involved, expansion details (in terms of new area added to existing facilities, if available) and most active players (in terms of number of instances).
• An estimate of the global, contract fill/finish capacity, by taking into consideration the capacities of various fill/finish service providers (as available on respective company websites), collected via secondary and primary research. The study examines the distribution of number of packaging units and volume of biologics filled, across various types of packaging containers (ampoules, cartridges, syringes, and vials), based on the size of the company / organization (small-sized, mid-sized and large) and geography (North America, Europe and Asia Pacific).
• An informed estimate of the annual demand for fill/finish of biologics, taking into account the top 20 biologics, based on various relevant parameters, such as target patient population, dosing frequency, dose strength, type of packaging container and volume of the packaging container of the abovementioned products.
• An analysis to identify the key performance indicators for service providers active in the domain, based on information gathered via secondary research (for top-ten pharmaceutical players) and primary research.
• A case study to highlight the benefits of using robotic / automated equipment for aseptic fill/finish processes; the study provides a list of equipment manufacturers providing robots suitable for pharmaceutical operations.
• A case study to highlight the role of ready-to-use packaging containers in aseptic fill/finish operations; the study provides a list of suppliers providing the ready-to-use components.
• A discussion on the potential growth areas, such as growing biopharmaceutical pipeline, increasing outsourcing of fill/finish operations, rising focus on self-administration enabling drug delivery devices and growing opportunities in Asia-Pacific region, which are likely to present in the coming years.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Competitive Landscape

5. Company Competitive Analysis

6. Biologics Fill / Finish Service Providers In North America: Company Profiles

7. Biologics Fill / Finish Service Providers In Europe: Company Profiles

8. Biologics Fill / Finish Service Providers In Asia-Pacific: Company Profiles

9. Partnerships And Collaborations

10. Recent Expansions

11. Capacity Analysis

12. Demand Analysis

13. Biologics Manufacturing And Fill / Finish: Key Performance Indicator Analysis

14. Market Sizing And Opportunity Analysis

15. Future Growth Opportunities

16. Case Study: Robotic Systems In Fill / Finish Operations

17. Case Study: Ready-To-Use Packaging Components In Aseptic Fill / Finish Operations

18. Conclusion

19. Interview Transcripts

20. Appendix 1: Tabulated Data

21. Appendix 2: List Of Companies And Organizations

Companies Mentioned

• AMRI
• APG Europe
• ARaymond Life
• AbbVie
• Adimmune
• Advanced BioScience Laboratories
• Afton Scientific
• Agilis Biotherapeutics
• Ajinomoto Bio-Pharma Services
• Akron Biotech
• Alcami
• Alcon
• Allergy Laboratories
• Amatsigroup
• Amgen
• Amicus Therapeutics
• Anchiano Therapeutics
• Apceth Biopharma
• Aptar Pharma
• Aptuit
• Arabio
• Arch Biopartners
• Aseptic Technologies
• Austrianova
• Axcellerate Pharma
• BAUSCH Advanced Technology Group
• Baccinex
• Bausch & Ströbel
• Baxter
• Bayer
• Becton Dickinson
• Bio Elpida
• Bio-Concept Laboratories
• BioConnection
• BioMARC
• BioPharma Solutions
• BioReliance
• BioTechLogic
• BioTechnique
• Biocon
• Biofabri
• Biogen
• Biomedical Advanced Research and Development Authority
• Biotechpharma
• Biovian
• Boehringer Ingelheim BioXcellence
• Bosch Packaging Technology
• Brammer Bio
• Bristol-Myers Squibb
• Bryllan
• Burrard Pharmaceuticals
• CARBOGEN AMCIS
• CMC Biologics
• Canada Peptide
• Cangene
• Capmatic
• Catalent Biologics
• Celgene
• Cell Culture Company
• Cellin Technologies
• Celonic
• Cenexi
• Cerbios-Pharma
• Cerium Pharmaceuticals
• Chase-Logeman
• China Gateway Biologics
• CinnaGen
• Cobra Biologics
• Coldstream Laboratories
• Cook Pharmica
• CordenPharma
• Cozzoli Machine Company
• Cytovance Biologics
• DM Bio
• DSM Pharmaceutical Products
• DWK Life Sciences
• Daikyo Seiko
• Dalton Pharma Services
• Datwyler Group
• Dr. Reddy’s Custom Pharma Services
• EMA Pharmaceuticals
• EUCODIS Bioscience
• EVER Pharma
• EirGen Pharma
• Emergent BioSolutions
• EuBiologics
• Eurofins Scientific
• Exelead
• FUJIFILM Diosynth Biotechnologies
• Fresenius Kabi Contract Manufacturing
• GLyPharma (acquired by Therachon)
• GTCR
• Gadea Pharmaceutical (acquired by AMRI)
• GenIbet Biopharmaceuticals
• Genentech
• Generic Specialities
• Gerresheimer
• GlaxoSmithKline
• Goodwin Biotechnology
• Grand River Aseptic Manufacturing
• Grninger
• HALIX
• HOOKIPA Pharma
• Hameln Pharmaceuticals
• Health Biotech
• Hepalink USA
• Hisun Pharmaceuticals USA
• Hitachi Chemical Advanced Therapeutics Solutions
• Hycult Biotech
• IDT Biologika
• IMA Group
• Immune Pharmaceuticals
• Infectious Disease Research Institute
• Intas Pharmaceuticals
• Integrity Bio
• JHL Biotech
• Johnson & Johnson
• Jubilant HollisterStier
• KABS Pharmaceutical Services
• Kaysersberg Pharmaceuticals (acquired by Recipharm)
• Kemwell Biopharma
• Kyowa Hakko Kirin
• LSNE Contract Manufacturing
• Lonza
• LuinaBio
• Lyophilization Technology
• M&O Perry
• MabPlex
• Madison Dearborn Partners
• MassBiologics
• Merck
• Microdermics
• Millmount Healthcare (acquired by PCI Services)
• Miltenyi Biotec
• Morgridge Institute for Research
• Mycenax Biotech
• Najt Technologies
• National Institutes of Health
• Ningbo Zhengli Pharmaceutical Packing
• Nipro PharmaPackaging
• Nitto Avecia Pharma Services
• Nitto Denko Avecia
• Nova Laboratories
• Novartis
• Novasep
• OPKO Health
• OPTIMA pharma
• Ompi
• Oncomed manufacturing
• Oncotec Pharma Produktion
• Oryn Therapeutics
• Oso BioPharmaceutical Manufacturing
• Ottawa Hospital Research Institute
• PCI Pharma Services
• PCT
• PSC Biotech
• PYRAMID Laboratories
• Pall Life Sciences
• Panacea Pharmaceuticals
• Paragon Bioservices
• Partners Group
• Patheon
• Penn Pharmaceutical Services
• Permira
• Pfizer
• Pharmaceutical Packaging Professionals
• Pierre Fabre
• Piramal Pharma Solutions
• Polpharma Biologics
• Polymun Scientific
• Praxis Pharmaceutical
• PrimaPharma
• Prince Sterilization Services
• Quality BioResources
• ROTA Verpackungstechnik
• Recipharm
• Regeneron Pharmaceuticals
• Reliance Life Sciences
• Rentschler Biotechnologie
• Rentschler Fill Solutions
• Roche
• Rommelag CMO
• RoslinCT
• SAFC
• SCHOTT
• SIRION Biotech
• SME Biotech Consulting
• Samsung BioLogics
• Samsung Bioepis
• Sanofi
• Saudi Biotechnology Manufacturing
• Selecta Biosciences
• Shenzhen Hepalink Pharmaceutical
• Sherpa Clinical Packaging (acquired by PCI Pharma Services)
• SiO2 Medical Products
• SialoCarb
• Siegfried Holding
• Singota Solutions
• Stevanato Group
• Swissfillon
• Symbiosis Pharmaceutical Services
• Symphogen
• Syngene
• Sypharma
• Tanvex BioPharma
• The Carlyle Group
• Therapure Biomanufacturing
• Thermo Fisher Scientific
• Transcoject
• Ultragenyx Pharmaceutical
• VGXI
• Vanrx Pharmasystems
• Vetter Pharma
• Vibalogics
• Vigene Biosciences
• Waisman Biomanufacturing
• Watson-Marlow Fluid Technology Group
• West Pharmaceutical Services
• WuXi Biologics
• Wuxi Fortune Pharmaceutical
• Wuxi Griffin Pharmaceuticals
• Yposkesi

For more information about this report visit https://www.researchandmarkets.com/r/viouv1

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics: Biopharmaceuticals